Biopharmaceuticals

San Diego – September 24, 2026 -- Viking Therapeutics plans to raise $400 million through simultaneous public offerings of $200 million in common stock and $200 million in convertible senior notes due 2032, with proceeds earmarked for its obesity drug pipeline.

Viking structures two independent capital raises with built-in flexibility

The biopharmaceutical company intends to grant underwriters a 30-day option to purchase an additional $30 million in common stock and a separate 30-day option for up to $30 million more in notes to cover over-allotments. Completion of one offering is not contingent on the other, giving Viking flexibility if market conditions shift. Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are serving as joint book-running managers for both transactions.

Washington – September 23, 2026 -- Bristol Myers Squibb (BMS) has joined the Rare Access Action Project (RAAP), adding a major biopharmaceutical player to a coalition working to resolve coverage and access barriers for rare disease patients.

RAAP expands coalition with BMS to tackle patient access barriers

RAAP, a coalition of patient advocates and life sciences companies, confirmed BMS's membership as part of its ongoing effort to develop policy solutions for structural access and coverage gaps affecting rare disease patients. Michael Eging, Executive Director of RAAP, said BMS brings a long history of scientific innovation and a strong commitment to patients facing serious and complex diseases.

Los Angeles – September 23, 2026 -- Armata Pharmaceuticals has received an additional $3.7 million in non-dilutive funding from the U.S. Department of War, pushing cumulative government support for its lead bacteriophage candidate AP-SA02 to approximately $32.4 million.

New funds mark first Phase 3-specific allocation under existing DoW award

The $3.7 million tranche represents the first capital earmarked specifically for Phase 3 execution under a previously announced award, following $28.7 million already disbursed. The funding flows through the Medical Technology Enterprise Consortium and is managed by the Naval Medical Research Command's Naval Advanced Medical Development unit, with backing from the Defense Health Agency and Joint Warfighter Medical Research Program.

Vancouver and Glil Yam, Israel – September 23, 2026 -- IM Cannabis Corp. (Nasdaq: IMCC) has regained compliance with Nasdaq's minimum bid price rule, closing a deficiency matter that had threatened its listing status on the exchange.

Nasdaq confirms compliance after 18-day trading streak

The company received written notice from Nasdaq Stock Market LLC on September 23, 2026, confirming it met the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2). The determination followed 18 consecutive business days, from August 27 to September 22, 2026, during which the closing bid price of IMC's ordinary shares stayed at or above $1.00.

Jacksonville, Florida – September 23, 2026 -- Theragen presented machine-learning findings at the Society for Minimally Invasive Spine Surgery (SMISS) 2026 Annual Forum showing that daily wear time of its ActaStim®-S bone growth stimulator predicts clinically meaningful pain improvement after spinal fusion surgery, with benefits plateauing around 13 hours of daily use.

Nearly 7,000 patients and 195,000 patient-days of data feed predictive model

The analysis drew on almost 7,000 patients and approximately 195,000 patient-day observations collected through ActaStim-S, a wearable electrical stimulation device paired with a digital health platform. A standardized device-to-electronic medical record pipeline achieved 99.2% data completeness across the dataset, according to Theragen.

Toronto – September 23, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has hit its 110-patient enrollment target for the pivotal Phase III MAVERIC trial ahead of its end-of-September guidance, and will now expand recruitment to as many as 150 patients.

Blinded review shows fewer recurrences than expected in pericarditis trial

A blinded review of patients randomized 1:1 to CardiolRxTM or placebo found a lower-than-anticipated rate of pericarditis recurrence, according to Cardiol. The MAVERIC Steering Committee recommended the enrollment increase to capture enough clinical events for a statistically robust efficacy read.

President and CEO David Elsley said the company is not aware of any change in routine clinical practice that would explain the reduced recurrence rate, calling the finding encouraging.

Suzhou, China – September 23, 2026 -- Innovent Biologics (HKEX: 01801) will present late-breaking Phase 3 data for its CLDN18.2-targeting antibody-drug conjugate IBI343/TAK-921 at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, running October 23-27.

Phase 3 gastric cancer trial secures late-breaking oral slot

Results from the registrational G-HOPE-001 study, comparing Arcotatug Tavetecan against treatment of physician's choice in previously treated advanced gastric or gastroesophageal junction adenocarcinoma, will be delivered as a late-breaking abstract (LBA77) during the October 23 proffered paper session. Dr. Kohei Shitara of Chiba, Japan, will present the first interim analysis of the randomized, open-label trial.

New Taipei City – September 23, 2026 -- Caliway Biopharmaceuticals (TWSE: 6919) said on September 21 that its Phase 2 CBL-0202DD trial of CBL-514 met its primary efficacy endpoint, delivering statistically significant pain reduction in patients with Dercum's Disease compared with placebo, in both the Full Analysis Set (FAS) and Per-Protocol (PP) populations.

CBL-514 Cuts Pain Scores by 3.1 Points at Week 20 Versus Placebo

In the FAS population, patients treated with CBL-514 achieved a mean pain-score reduction of 3.1 points at Week 20, versus 1.9 points for placebo (p=0.005). In the PP population, the same 3.1-point reduction was measured against a 1.4-point placebo response (p=0.0002).

Pune, India – – September 22, 2026 -- The global exosomes market is set to grow nearly tenfold over the next decade, expanding from USD 230.55 million in 2025 to USD 2,250 million by 2034, according to a new analysis from Maximize Market Research. The projected 28.8% compound annual growth rate between 2026 and 2034 places exosome technology among the fastest-expanding segments in biopharmaceutical R&D.

Drug delivery pipelines drive commercial momentum

Pharmaceutical and biotechnology companies are expanding exosome-related pipelines as the nanosized extracellular vesicles gain traction as targeted carriers for drugs, proteins, and RNA. Rising investment in biotechnology and advances in isolation, characterization, and engineering technologies are pushing exosomes beyond research settings into drug development and regenerative medicine applications.

Pune, India – September 22, 2026 -- The global lupus nephritis market was valued at $1.96 billion in 2025 and is projected to reach $4.08 billion by 2034, expanding at a compound annual growth rate of 8.5% through the forecast period, according to a new analysis by Maximize Market Research.

North America leads treatment adoption on strong pharmaceutical research capabilities

North America holds the leading position in the market, supported by advanced healthcare infrastructure and higher awareness of autoimmune diseases. The United States drives regional demand through its established pharmaceutical industry and strong clinical research activity, while Canada contributes through its developed healthcare system focused on autoimmune disease management.